Benitec Biopharma Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended June 30, 2022 (not calendar 2021 Q4). The company is a development-stage biotechnology business focused on DNA-directed RNA interference (ddRNAi) and gene therapy. Its lead candidate, BB-301, is an AAV-based “silence and replace” therapy for oculopharyngeal muscular dystrophy (OPMD); it remained in preclinical development. BB-301 has U.S. and EU orphan drug designations.
Financial performance and position
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $73,000 | $59,000 |
| Research and development expense | $11.272 million | $7.020 million |
| General and administrative expense | $6.646 million | $6.512 million |
| Total operating expenses | $17.927 million | $13.655 million |
| Net loss | $18.208 million | $13.882 million |
| Operating cash used | $15.899 million | $12.832 million |
- Revenue was licensing revenue; the company reported no product sales. No meaningful product margin is reported.
- Cash and cash equivalents were $4.062 million at June 30, 2022, down from $19.769 million a year earlier. Including restricted cash, year-end cash was $4.076 million.
- Total assets were $5.973 million; total liabilities were $3.091 million. The company reported no borrowings and no credit facility. Lease liabilities totaled $811,000, including $252,000 current.
- Accumulated deficit was $148.327 million. The company said available cash was insufficient to fund operations for the next 12 months after the filing date without additional financing.
Material changes and business developments
- Net loss increased by $4.326 million year over year, principally as R&D expense rose $4.252 million, mainly for BB-301/OPMD development. G&A increased modestly; royalties and license fees fell to $9,000 from $123,000.
- Operating cash use increased by $3.067 million. FY2021 financing proceeds were $22.522 million net; there was no financing cash inflow in FY2022.
- The company reported interim results from its canine BB-301 pilot dosing study: optimized administration and methods produced reported pharyngeal-muscle transduction improvements versus a prior licensee’s study. These were nonclinical findings, not human clinical results.
- Management stated that it continued planning for BB-301 clinical development in the second half of 2022, subject to completion of enabling work and financing.
Outlook, risks, and notable items
- The independent auditor included a substantial-doubt going-concern paragraph. Management was seeking additional capital, but financing success was not assured. Failure to raise funds could force delays, reductions, or discontinuation of development programs.
- The company expected continued losses and no significant product-sale revenue for the foreseeable future. It provided no numerical revenue, earnings, or cash-flow guidance.
- COVID-19 had delayed BB-301 IND-enabling work and could continue to affect studies, vendors, trial timing, and access to financing. The filing also describes gene-therapy delivery, safety, regulatory, manufacturing, collaboration, competition, and intellectual-property risks.
- BB-301’s efficacy and durability are unproven in humans. AAV-related immune responses and the specialized administration procedure may present safety or practical challenges.
- Accrued R&D costs were identified as a critical audit matter because estimating unbilled vendor work required significant judgment. Management reported disclosure controls and internal control over financial reporting as effective; the auditor was not required to audit internal control effectiveness.
Most important facts for investors to verify
- Whether the company subsequently raised enough capital to fund operations and meet near-term obligations, and the resulting dilution or financing terms.
- Whether BB-301’s enabling studies were completed and whether a clinical trial began as planned; verify regulatory filings, trial registration, and actual human data.
- How much cash remained after June 30, 2022 and the company’s updated cash runway and operating plans.
- Whether the reported canine study findings translate into reproducible human safety and therapeutic benefit.
- Any material changes in manufacturing arrangements, licensing rights, or the third-party AAV patent issue identified as potentially relevant to commercialization.